Pharmaceutical biotechnology for target validation -- Generation of transgenic animals / Brian P. Zambrowicz, Kathleem H. Holt, D. Wade Walke [and others] -- Target validation in chemogenomics / Tom Y-H. Wu, Sheng Ding -- Target validation for biopharmaceutical drug discovery -- Cetuximab (Erbitux®), an anti-epidermal growth factor receptor antibody for the treatment of metastic colorectal cancer / Zhenping Zhu -- Monoclonal antibody to HER-2 in breast cancer / Francisco J. Estava, Gabriel N. Hortobagyi -- Validation of TNF as a drug target in inflammatory bowel disease / Michael J. Elliot -- Anti-CCL-2/ MCP-I: directed biologicals for inflammatory and malignant diseases / Anuk Das, Li Yan -- Targeting IL-12p40 for immune-mediated disease / Jacqueline Benson -- The GP/IIIa antagonist abciximab for acute percutaneous coronary intervention / Robert E. Jordan -- Validating targets of small molecule approaches -- Epidermal growth factor receptor (EGFR) inhibitor for oncology: discovery and development of erlotinib / Kenneth K. Iwata, Shannon E. Beard, John D. Haley -- Progress in achieving proof of concept for p38 kinase inhibitors / Jerry L. Adams, John C. Lee -- IKK-2/NF-kB-dependent transciption / F. Christopher Zusi, William J. Pitts, James R. Burke -- TNF signaling pathway inhibitors for inflammation-CCR2 antagonists / Kevin J. Duffy, Connie L Erickson-Miller -- Orally bioavailable glycoprotein IIb/IIIa anatgonists: a negative case study / Dietmar A. Seiffert, Jeffrey T. Billheimer.
This resource is supported by the Institute of Museum and Library Services under the provisions of the Library Services and Technology Act as administered by State Library of Iowa.